$85.33
+0.40(0.47%)
Mkt Cap $7.0B
$21.05
$95.03
52-Week Range
At A Glance
1
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the b...
2
Most recently: Entry Into a Material Definitive Agreement. On February 26, 2026, Kymera Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “TD Cowen Sales (2026-02-26).
$7.0B
Market Cap
$38M
Revenue
-$301M
Net Income
Employees208
Fundamentals
How The Business Makes Money
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001815442
ISINUS5015751044
CUSIP501575104
Phone857 285 5300
Address200 Arsenal Yards Boulevard, Watertown, MA, 02472, US
SEC EDGAR